CLOSE
MENU
Chordia Therapeutics Inc.
Investor Relations
IR News
IR News
サブ-ナビゲーション
Company
Science/Pipleline
News
Investor Relations
Management Policies
Financial Information
IR Library
Stock Information
IR Calender
現在位置:
IR News
IR FAQ
Disclaimer
Career
Contact
Privacy Policy
Term of use
Sitemap
IR News
Jan 14, 2025
Non-consolidated Financial Results for the Three Months Ended November 30, 2024 [Japanese GAAP]
(432KB)
Jan 10, 2025
Rogocekib for the treatment of Refractory or Relapsed Acute Myologic Lymphoma(AML) has been granted Orphan Drug Designation (ODD) in the US by the FDA
(272KB)
Dec 12, 2024
By FISCO Corporation Notice of Distribution of Our Corporate Research Report
(267KB)
Nov 29, 2024
Corporate Governance Report
(659KB)
Nov 20, 2024
Announcement of International Nonproprietary Name (INN) for CTX-712
(277KB)
Oct 28, 2024
Chordia announces the Release of a Transcript of the Earnings Briefing for the Fiscal Year Ended August 2024
(281KB)
Oct 15, 2024
Fiscal year ended August 2024 Financial Results Presentation
(1,465KB)
Oct 11, 2024
Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2024 [Japanese GAAP]
(538KB)
Oct 11, 2024
Chordia to Present Results of Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2024 The 86th Annual Meeting of the Japanese Society of Hematolog
(283KB)
Oct 01, 2024
Announcement of Presentation on Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 86th Annual Meeting of the Japanese Society of Hematology
(281KB)
Jul 23, 2024
Chordia wins the Minister of Education, Culture, Sports, Science and Technology Award at the Japan Startup Awards 2024.
(610KB)
Jul 16, 2024
Non-consolidated Financial Results for the Nine Months Ended May 31, 2024 [Japanese GAAP]
(348KB)
VIEW IR NEWS
ページの先頭へ
ページの先頭へ
menu
gnavi-box